Who we help accelerate
Accelerate the scale up of your genetic testing & unlock the value in your data.
NGS Assay & Equipment Manufacturers
Bring new tests to market and scale up testing fast.
Accelerate your research breakgthroughs and novel drug launches.
Non-Profits and Government Agencies
Accelerate your research breakthroughs and unlock the value in your data.
How we can help
Clinical Interpretation & Reporting
Secondary & Tertiary analytics tools enabled by expert clinical services.
Effectively navigate and grow in the changing regulatory environment.
NGS Assay Development & Expansion
Bring new tests to market and scale-up fast.
Companion Diagnostic Development & Scaling
Develop better diagnostics that scale faster, accelerating novel drug uptake.
Harmonize and augment your data to unlock the value within.
Use cutting edge technology to make new discoveries and breakthroughs faster.
Our cutting-edge technology suite
Our tertiary analytics & reporting tool for clinical NGS diagnostics.
Our best in class, IVD-grade variant interpretation knowledge base.
Our Trusted Research Environment (TRE) for bioinformatic analysis & pipeline development.
Our data harmonization and secure sharing platform.
Our award winning reference genome tool.
High throughput for PCR made simple.
Our in-house expert teams
Supporting diagnostic labs to start and scale-up their NGS testing.
Supporting clinical diagnostic labs and diagnostic test developers to navigate the changing regulatory environment.
Supporting health & life science companies to combine and harmonize their data.
Supporting researchers and diagnostic developers to build better workflows.
Supporting researchers to run efficient and effective studies.
Our company
Publications, whitepapers, webinars, videos, and more.
The latest from the precision medicine experts at Velsera.
Interested in joining the team? Explore careers here.
Visit our legal section for all of the details.
Home | Resources | Videos | The Variant Interpretation for Cancer Consortium (VICC) – FDA LDT Discussion
Drs. Eric Konnick, Yassmine Akkari, and Andy Bredemeyer discuss the recent decisions and actions surrounding FDA governance of laboratory developed tests (LDTs) – the Final Rule, current lawsuits, and what it all means for those of us in cancer genomics.